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SLEDAI-2KAbstract Background: Cell free deoxyribonucleic acid (cf-DNA) is now emerging as a useful tool
for non-invasive diagnostic methods related to a wide range of clinical conditions including autoim-
mune diseases.
Aim of the work: To estimate the concentration of plasma cf-DNA in rheumatoid arthritis (RA)
and systemic lupus erythematosus (SLE) patients compared with healthy subjects and to correlate
the results with clinical and laboratory parameters of disease activity.
Patients and methods: The study included 30 RA patients, 35 SLE patients and 25 matched con-
trol. Plasma cf-DNA was estimated by real-time quantitative PCR. Disease activity parameters for
each disease were assessed; Disease Activity Score-28 (DAS28) was used for RA and SLE disease
activity index 2000 (SLEDAI-2K) for SLE patients.
Results: The RA patients (F:M 4:1) had a mean age of 36.8 ± 9.6 years and disease duration of
8.3 ± 1.1 years while the SLE patients (F:M 7.75:1) had a mean age of 35.6 ± 8.8 years and disease
duration of 8.1 ± 0.87 years. There was a highly significant increase in the cf-DNA level in SLE
patients (17.33 ± 2.4 ng/ml) and RA patients (11.15 ± 2.3 ng/ml) compared to the level in the con-
trol (4.15 ± 1.4 ng/ml) (p= 0.0005). The cf-DNA significantly correlated with the erythrocyte sed-
imentation rate (ESR) (p= 0.04), C-reactive protein (p= 0.04) and the DAS28 (p= 0.005) in the
RA patients and with the ESR (p= 0.03), anti-ds-DNA (p= 0.008), complement-4 (p= 0.04) and
SLEDAI-2K (p= 0.002).
Conclusion: The increased cf-DNA implicates a possible role in the pathogenesis of both RA and
SLE and appears to be a useful marker of disease activity in addition to other laboratory tests.
 2016 Egyptian Society of Rheumatic Diseases. Publishing services provided by Elsevier B.V. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Circulating cell-free deoxyribonucleic acid (cf-DNA), defined
as extracellular DNA occurring in blood serum or plasma,
has been widely studied and is considered as a potential bio-
marker for the detection and monitoring of various human dis-
eases such as stroke [1], myocardial infarction [2], sepsis [3],
acute pancreatitis [4], as well as cancer [5]. Circulating cf-
DNA molecules are present in only limited amounts in blood
of healthy individuals, since dying cells and remnants of dead
cells are efficiently removed, mainly in the liver [6]. Reactive
oxygen species are implicated as a cause of damage to DNA,
including breaking of single and double strands, releasing of
free nucleobases, chemical changes of nucleobases, and modi-
fication of sugar moieties [7]. The first report on the presence
of circulating cf-DNA was published decades ago in 1948 [8],
they detected the presence of free nucleic acids in plasma. They
were able to detect free DNA and RNA in the plasma of
healthy individuals and patients. Unfortunately, their work
passed unnoticed because of lack of clear understanding about
circulating nucleic acid at that time. Later it became clear that
analyzing and quantitating cell-free plasma DNA could serve
as a valuable diagnostic tool [9].
Rheumatoid arthritis (RA) is an inflammatory, destructive
joint disease in which a broad range of extra-articular manifes-
tations may occur. Serological tests, most notably the detec-
tion of anti-citrullinated protein antibodies (ACPA) and
rheumatoid factor (RF), play an important role in diagnosing
RA. The ACPA were found in up to 75% of RA patients [10].
RF is present in 60–90% of patients with established RA and
in up to 50% of patients with early RA [11]. Anti-nuclear anti-
bodies (ANAs) occur in approximately 30% of patients with
RA, as determined by nuclear immunofluorescence. Because
complexes of anti-DNA antibodies with microbial or self
DNA are implicated in the activation of B cells by Toll-like
receptors and surface IgM RF, it is possible to hypothesize
that anti-DNA antibodies and DNA represent such an
antibody-antigen system in vivo [12]. Although, the introduc-
tion of ACPA and RF tests has greatly contributed to improv-
ing the early diagnosis of RA, additional molecular markers
are needed, to identify the seronegative patients, to differenti-
ate between disease phenotypes, to predict responsiveness to
treatment and to improve prognosis [13].
Systemic lupus erythematosus (SLE) is a prototypic
autoimmune disease with a complex pathogenesis involving
multiple genetic and environmental factors. The disease is
characterized by enhanced autoantibody production, abnor-
malities in function of immune-inflammatory system and
inflammatory manifestations in several organs [14]. Cell death
has been regarded as an important event in the pathogenesis as
it leads to release of antigens as nucleic acids for immune com-
plex formation and that DNA-antibody complexes in the cir-
culation are one of the hallmarks of SLE [15]. It is well
known that auto-antibodies can target DNA and the DNA
auto-antibody complex in the circulation plays a crucial role
in SLE [16] and may trigger a cascade of immune responses
against body tissue in SLE patients [17]. In a study on Egyp-
tian SLE patients there was an apparent higher incidence of
secondary antiphospholipid syndrome in those with positive
anti-DNA [18]. The anti-dsDNA may serve as potential reli-
able and non invasive markers of SLE disease activity andrenal involvement in Sharkia governorate and may help in
avoiding unnecessary renal biopsies [19]. In another study, of
the anti-chromatin autoantibodies, anti-nucleosome and not
anti-DNA were associated with active lupus disease and corre-
late with the degree of renal affection [20]. The aim of this
study was to measure the levels of plasma cf-DNA in patients
with RA and SLE compared with levels in healthy subjects and
to find any correlation with disease activity in both diseases.
2. Patients and methods
We evaluated 30 RA and 35 SLE patients selected from the
outpatient clinics and inpatient units of Rheumatology, Phys-
ical Medicine and Rehabilitation Department, Zagazig
University Hospitals, during the period from May 2014 to
December 2015. Age and gender matched 25 healthy volunteer
subjects were included in this study as control. A written
informed consent was obtained from patients after explanation
of the purpose and procedures of the study. All RA patients
fulfilled the 2010 Classification Criteria for RA [21]. All SLE
patients satisfied the Systemic Lupus International Collaborat-
ing Clinics (SLICC) revised SLE classification criteria [22]. The
disease activity in RA patients was evaluated according to Dis-
ease Activity Score 28 (DAS28) [23] and in SLE according to
the SLE disease activity index 2000 (SLEDAI-2K) [24].
Patients with a history of stroke, cancer, myocardial infarc-
tion, hepatic, cardiac or renal impairment and diabetic patients
were excluded. Patients with other autoimmune diseases were
also excluded. The study was approved by the ethics commit-
tee of the Zagazig University Hospitals, Faculty of Medicine,
Zagazig University.
All Patients were subjected to complete history taking with
stress on disease duration, complete physical and muscu-
loskeletal examination, Health Assessment Questionnaire
(HAQ) [25] assessment, routine laboratory investigations
including complete blood count (CBC), liver and kidney func-
tion tests, 24 h urine protein for SLE patients, erythrocyte sed-
imentation rate (ESR), C-reactive protein (CRP), rheumatoid
factor (RF) and serum complement C3 and C4 levels. The
ANA and anti-double stranded DNA (anti-dsDNA) were
measured by indirect immunofluorescence assay (IIF)
(Immuno-Diagnostic USA).
Plasma cf-DNA analysis by real-time quantitative poly-
merase chain reaction (PCR): samples were taken from both
patients and controls. Five ml of venous blood was collected
under complete aseptic conditions and put into sterile vacu-
tainer EDTA tubes. The samples were processed immediately.
The blood samples were centrifuged at 1600g for 10 min.
Plasma layer was obtained and transferred to new sterile tubes.
A further centrifugation step at 1600g for 10 min was per-
formed to spin down any insoluble remnants in the plasma.
Plasma cell-free DNA was then extracted from the 400 ll of
plasma sample using the high pure PCR template preparation
kit (Roche Diagnostics, Germany), following the manufactur-
ers protocol. The DNA preparations were eluted in 100 ll elu-
tion buffers and the purified DNA was stored at 80 C until
further use. For analyzing cf-DNA, the GAPDH
(glyceraldehydes-3-phosphate dehydrogenase) housekeeping
gene has been used with forward 50-CCCCACACACATG
CACTT-ACC-30, reverse 50-CCTAGTCCCAGGGCTTT
GATT-30 primers and 50-MGB-TAGGAAGGACAGG
Table 1 The characteristics of the rheumatoid arthritis and
systemic lupus erythematosus patients.
Variable RA SLE
Mean ± SD (n= 30) (n= 35)
ESR (mm/h) 59.3 ± 8.5 75.5 ± 10.5
CRP (mg/L) 10.2 ± 2.9 5.2 ± 2.4
Anti-dsDNA (IU/ml) – 57.51 ± 7.44
C3 (mg/dl) – 39.22 ± 11.02
C4 (mg/dl) – 18.22 ± 4.75
HAQ 2.1 ± 0.5 1.6 ± 0.4
DAS28 5.4 ± 0.7 –
SLEDAI – 18.3 ± 9.2
cf-DNA (ng/ml) 11.15 ± 2.3 17.33 ± 2.4
RA: rheumatoid arthritis, SLE: systemic lupus erythematosus,
HAQ: Health Assessment Questionnaire, DAS28: Disease Activity
Score 28, ESR: erythrocyte sedimentation rate, CRP: C-reactive
protein, Anti-dsDNA: anti-dsDNA, C: complement, SLEDAI:
SLE disease activity index, cf-DNA: cell-free DNA.
Figure 1 Level of cell-free deoxyribonucleic acid (cf-DNA) in
rheumatoid arthritis (RA) and systemic lupus erythematosus
(SLE) patients as well as in control.
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used as a template for the real-time PCR analysis. The PCR
was performed using the ABI step one (Applied Biosystems,
ABI). The real-time PCR was carried out in 25 ll of total reac-
tion volume containing 5 ll of DNA, 12.5 ll of TaqMan
Universal PCR Master Mix, four primers, and two probes
using two-minute incubation at 50 C. The reaction was pro-
cessed by an initial denaturation step at 95 C for 10 min
and 40 cycles of 1 min at 60 C and 15 s at 95 C. For the mul-
tiplex TaqMan amplification of the concentration of primers
and probes was optimized. The optimal concentration of the
primers and probes for duplex real-time PCR is 0.6 lM for
each primer and 0.4 lM for each probe [27]. The positive reac-
tion was detected by the accumulation of a fluorescent signal.
The cycles required for the fluorescent signal to cross the
threshold are defined as cycle threshold (CT). The CT values
can also be converted into quantities according to standard
curves generated by dilution of human genomic DNA with a
known concentration for generating the standard curves
[28,29].
2.1. Statistical analysis
IBM SPSS statistics (V. 23.0, IBM Corp., USA, 2015) was
used for data analysis. Data were expressed as mean ± SD
for quantitative parametric measures in addition to both num-
ber and percentage for categorized data. Comparison between
two independent mean groups for parametric data was done
using Student t test and among more than 2 patient groups
using an Analysis of Variance (ANOVA). Chi-square test
was used to study the association between each 2 variables
or comparison between 2 independent groups as regards the
categorized data. The probability of error at 0.05 was consid-
ered significant, while at 0.01 and 0.001 was considered highly
significant.
3. Results
The study included three groups: RA group (24 women and 6
men; F:M 4:1) with a mean age of 36.8 ± 9.6 years (20–
52 years) and mean disease duration of 8.3 ± 1.1 years (7–
10 years), SLE group (31 women and 4 men; F:M 7.75:1) with
a mean age of 35.6 ± 8.8 years (22–50 years) and mean disease
duration of 8.1 ± 0.87 years (7–9 years) and control group (20
women and 5 men; F:M 4:1) with a mean age of 37.8
± 9.7 years (21–57 years). The control group was age
(p= 0.62) matched with the 2 groups of patients.
Baseline clinical and laboratory variables of the patients are
shown in Table 1. There was a highly significant increase in the
cf-DNA level in SLE patients (17.33 ± 2.4 ng/ml) and RA
patients (11.15 ± 2.3 ng/ml) compared to the level in the con-
trol (4.15 ± 1.4 ng/ml) (p= 0.0005) (Fig. 1).
There was a significant correlation between cf-DNA and
disease variables in RA patients (Table 2) including ESR,
CRP, and DAS-28 (Fig. 2) while not with patient age, disease
duration and HAQ. Also, significant correlations were found
between cf-DNA and disease variables in SLE patients
(Table 3) including ESR, CRP, anti- ds-DNA titer, C3 level,
C4 level and total SLEDAI (Fig. 3), while, there were no cor-
relations between cf-DNA levels and patient age and disease
duration.4. Discussion
The origin and exact mechanism of cf-DNA release are still
controversial. Accumulation of cf-DNA in plasma might result
from an excessive release of DNA caused by massive cell death
or inefficient elimination of dead cells and during inflamma-
tion. Thus, the concentration of plasma cf-DNA might reflect
the magnitude of cell damage and inflammation. The free
mitochondrial DNA could promote endothelial dysfunction,
as well as other side effects on the vascular system through
the activation of the toll-like receptor 9 (TLR9). TLR9 is
Table 2 Correlation of cf-DNA with clinical and laboratory
variables in the rheumatoid arthritis group.
Variable cf-DNA (ng/ml)
R p
Age (years) 0.23 (0.32)
Disease duration (years) 0.2 (0.37)
HAQ 0.43 (0.3)
ESR (mm/h) 0.38 (0.04)
CRP (mg/L) 0.34 (0.04)
DAS-28 0.52 (0.005)
cf-DNA: cell-free DNA, HAQ: Health Assessment Questionnaire,
ESR: erythrocyte sedimentation rate, CRP: C-reactive protein,
DAS28: Disease Activity Score 28.
Bold values are significant at p<0.05.
Figure 2 Correlation between cell-free deoxyribonucleic acid (cf-
DNA) and Disease Activity Score-28 (DAS-28) in rheumatoid
arthritis (RA) patients (number = 30).
Table 3 Correlation of cf-DNA with clinical and laboratory
variables in the systemic lupus erythematosus group.
Variable cf-DNA (ng/ml)
R p
Age (years) 0.28 (0.26)
Disease duration (years) 0.25 (0.22)
ESR (mm/1sth) 0.4 (0.03)
CRP (mg/l) 0.43 (0.02)
Anti-dsDNA (IU/ml) 0.5 (0.008)
C3 (mg/dl) 0.33 (0.04)
C4 (mg/dl) 0.34 (0.04)
SLEDAI 0.62 (0.002)
cf-DNA: cell-free DNA, ESR: erythrocyte sedimentation rate,
CRP: C-reactive protein, DAS28: Disease Activity Score 28, Anti-
dsDNA: anti-dsDNA, C: complement, SLEDAI: systemic lupus
erythematosus disease activity index.
Bold values are significant at p<0.05.
Figure 3 Correlation between cell-free deoxyribonucleic acid (cf-
DNA) and systemic lupus erythematosus disease activity index
(SLEDAI) in SLE patients (number = 35).
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tocytes, and epithelial and endothelial cells). It is localized
intracellularly and recognizes non-methylated dinucleotides
of viral, bacterial, and mitochondrial DNA [30]. Alteration
of cf-DNA levels has been reported for autoimmune diseases
such as SLE, systemic sclerosis, Sjo¨gren’s syndrome [31] and
RA [32].In the present study a highly significant difference was
found between each of RA and SLE patients, and controls
as regards the levels of cf-DNA. Our results agreed with that
of Zhong and his colleagues [32] who found that the serum
levels of cf-DNA were significantly higher in the RA group
than in the control. Patients with RA showed a highly substan-
tial increase in circulating DNA concentrations in the plasma
and in the serum, which were in the high range of those
reported in neoplasia or preeclampsia. Dunaeva et al. evalu-
ated the concentration of cf-DNA from sera of patients with
early RA, established RA, relapsing-remitting multiple sclero-
sis patients and healthy subjects. Their results revealed that
reduced levels of cf-DNA were more observed in patients with
established RA. They reported that measurement of cf-DNA
can distinguish established from early RA patients [13]. Thus,
cf-DNA may serve as a biomarker in RA. In contrast cf-DNA
was high in our RA patients with established disease and this
can be explained with their active disease.
Our results showed significant correlation between cf-DNA
levels and the disease variables including ESR, CRP and
DAS28 in RA patients. Our results agreed with Leon et al.
[33], who found higher concentrations of free DNA in both
plasma and synovial fluid in RA patients than in healthy sub-
jects and it correlated with the symptom severity and the level
of the tissue damage. Our results showed significant correla-
tion between cf-DNA levels and the disease variables in SLE
patients including ESR, CRP, anti-ds-DNA titer, C3, C4 and
SLEDAI. Our results agreed with Atamaniuk and his co-
workers [34], who demonstrated a significantly increased cf-
DNA plasma level in SLE patients. However, they found no
correlation between disease activity and anti-dsDNA, anti-
ssDNA and anti-nucleosome antibody concentrations. Our
results agreed with Zhang and his co-workers [35], who found
a significantly higher cf-DNA concentration in SLE patients
than that observed in the healthy control especially those with
active lupus nephritis. Our results agreed also with that of
Hendy and her co-workers [36], who found a significantly
higher serum level of cf-DNA in SLE patients compared with
healthy controls and a positive correlation was found with
parameters of disease activity. Furthermore, they found a sig-
nificant reduction in serum level of cf-DNA after specific drug
therapy for SLE disease indicating a prognostic value. Simi-
larly, Tug and her colleagues showed a significantly higher
Plasma cell-free DNA and its correlation with disease activity 299cf-DNA concentration in SLE patients compared to control
[37]. Our findings support that the measurement of cf-DNA
appear to be a useful marker of disease activity in addition
to the laboratory tests used in SLE and RA. Future longitudi-
nal studies on a larger number of patients are needed to verify
the presented results with in-depth studying of the relation to
clinical manifestations.
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